Dendritic cells as key targets for immunomodulation by Vitamin D receptor ligands

Luciano Adorini, Giuseppe Penna, Nadia Giarratana, Andrea Roncari, Susana Amuchastegui, Kenn C. Daniel, Milan Uskokovic

Research output: Contribution to journalArticlepeer-review


Vitamin D receptor (VDR) ligands, in addition to controlling calcium metabolism, exert important effects on the growth and differentiation of many cell types and possess pronounced pro-tolerogenic immunoregulatory activities. VDR ligands can act directly on T cells, but antigen-presenting cells (APCs), and in particular dendritic cells (DCs), appear to be primary targets for their tolerogenic properties. The capacity of VDR ligands to target APCs and T cells is mediated by VDR expression in both cell types and by the presence of common targets in their signal transduction pathways, such as the nuclear factor NF-kB that is down-regulated in APCs and in T cells. VDR ligands can induce in vitro and in vivo tolerogenic DCs able to enhance CD4 +CD25 + suppressor T cells that, in turn, inhibit Th1 cell responses. These mechanisms of action can explain some of the immunoregulatory properties of VDR ligands, and are potentially relevant for the treatment of Th1-mediated autoimmune diseases and allograft rejection.

Original languageEnglish
Pages (from-to)437-441
Number of pages5
JournalJournal of Steroid Biochemistry and Molecular Biology
Publication statusPublished - May 2004


  • APC
  • Dendritic cell
  • VDR

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology


Dive into the research topics of 'Dendritic cells as key targets for immunomodulation by Vitamin D receptor ligands'. Together they form a unique fingerprint.

Cite this